COLOPLAST A/S [CBOE] overview

On 14 March 2025, Coloplast Finance B.V. held its Annual General Meeting. At the Annual General Meeting, the sole shareholder, Coloplast A/S, approved the annual report for the financial year 2023/24. In addition, Ernst & Young Accountants LLP was appointed as auditor for Coloplast Finance B.V. Attachment 02-2025-decisions-at-the-annual-general-meeting-coloplast-finance-bv...

2024/25 Interim financial results, Q1 2024/25 1 October 2024 - 31 December 2024 Coloplast delivered 8% organic growth and an EBIT margin 1 of 27% in Q1, in line with expectations. Reported revenue in DKK grew 6% and included negative impact from the divestment of Skin Care and currencies. Organic growth rates by business area: Ostomy Care 7%, Continence Care 7%, Voice and Respiratory Care 11%, Advanced Wound Care 12% and Interventional Urology 1%. Growth in Chronic Care was driven by solid...

On 13 November 2024, Malene Lunddal Hansen was elected to the management board in Coloplast Finance B.V. replacing Hea Vinskov. Malene Lunddal Hansen is Senior Director for Tax & Compliance in the Coloplast group. The management board in Coloplast Finance B.V. hereafter consists of: Henrik Deneke, Anton Mikkelsen and Malene Lunddal Hansen. Attachment 07_2024_Change_in_management_board...

Hereby please find the Annual Report 2023/24 for the group of Coloplast A/S. Attachment 07_2024_Annual_Report_2023-24...

H1 2023/24 Interim financial results, H1 2023/24 1 October 2023 - 31 March 2024 Coloplast delivered a solid Q2 with 8% organic growth and an EBIT margin 1) of 27%. Reported revenue in DKK grew 9% with 4%-points contribution from Kerecis (underlying growth of around 35%), partly offset by currencies. Organic growth rates by business area: Ostomy Care 7%, Continence Care 8%, Voice and Respiratory Care 13%, Advanced Wound Care 8% (Advanced Wound Dressings 8%) and Interventional Urology 5%....

Q1 2023/24 Interim financial results, Q1 2023/24 1 October 2023 - 31 December 2023 Coloplast delivered a solid Q1 with 8% organic growth and an EBIT margin 1) of 28%. Reported revenue in DKK grew 8% with 4%-points contribution from Kerecis (underlying growth of around 35%), offset by negative impact from currencies. Organic growth rates by business area: Ostomy Care 8%, Continence Care 8%, Voice and Respiratory Care 7%, Advanced Wound Care 9% (Advanced Wound Dressings 9%) and Interventional...

On 24 January 2024, Coloplast Finance B.V. held its Annual General Meeting. At the Annual General Meeting, the sole shareholder, Coloplast A/S, approved the annual report for the financial year 2022/23. In addition, Ernst & Young Accountants LLP was appointed as auditor for Coloplast Finance B.V. Attachment 01_2024_Decisions_at_the_Annual_General_Meeting_Coloplast_Finance_B.V....

Today, 24 January 2024, Coloplast Finance B.V. held its Annual General Meeting at which Ernst & Young Accountants LLP was elected as Coloplast Finance B.V.’s auditors. Attachment 02_2024_Change_of_Auditor_Coloplast_Finance_B.V....